Teva Pharmaceutical Industries Limited

Technion Research & Development Foundation Ltd

Finetech Laboratories Ltd.

Svc Pharma LP

Isp Investments Inc.

Purdue Pharma L.p.

Euro-Celtique S.a.

Finetech Pharmaceutical Ltd

Gennady Nisnevich

Boris Pertsikov

Igor Rukhman

Arie L Gutman

Boris Tishin

Marina Etinger

Ben-Zion Dolitzky

Julia Kaftanov

Irina Fedotev

Mark Gandelman

Lev Yudovich

Ram Khanolkar

Kseniya Kulbitski

Alexander Artaryan

Shlomit Wizel

Igor Zaltzman

Michael Yuzefovich

Ben Zion Dolitzky

Igor Zaltsman

Anton Shalimov

Maxim Sotrihin

Dina Blasberger

Judith Aronhime

Robert J Kupper

Marioara Mendelovici

Valerie Niddam-Hildesheim

Lev Yudovitch

Elaine Melissa Schuster

Alexander Vilensky

Alex Vilenski

Albay Agazade

Boris Pertzikov

The present invention provides a halo-de-carboxylation process for the preparation of organic chlorides, organic bromides and mixtures thereof, from their corresponding carboxylic acids, using a chlorinating agent selected from trichloroisocyanuric acid (TCCA), dichloroisocyanuric acid (DCCA), or combination thereof, and a brominating agent.

Process for the preparation of organic halides

The present invention provides a process for the preparation of organic bromides, by a radical bromodecarboxylation of carboxylic acids with a bromoisocyanurate.

Process for the preparation of organic bromides

Methods for making trans-(&#x2212;)-&#x394;-tetrahydrocannabinol and trans-(+)-&#x394;-tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(&#x2212;)-&#x394;-tetrahydrocannabinol composition is prepared by allowing a composition comprising (&#xb1;)-&#x394;-tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(&#x2212;)-&#x394;-tetrahydrocannabinol composition comprising at least about 99% by weight of trans-(&#x2212;)-&#x394;-tetrahydrocannabinol based on the total amount of trans-(&#x2212;)-&#x394;-tetrahydrocannabinol and trans-(+)-&#x394;-tetrahydrocannabinol. The invention also relates to methods for treating or preventing a condition such as pain comprising administering to a patient in need thereof an effective amount of a trans-(&#x2212;)-&#x394;-tetrahydrocannabinol having a purity of at least about 98% based on the total weight of cannabinoids.

[object Object]

The present invention provides new stable crystalline N-iodoamides-1-iodo-3,5,5-trimethylhydantoin (1-ITMH) and 3-iodo-4,4-dimethyl-2-oxazolidinone (IDMO). The present invention further provides a process for the preparation of organic iodides using N-iodoamides of this invention and recovery of the amide co-products from waste water.

Methods for making trans-(&#x2212;)-&#x394;-tetrahydrocannabinoI and trans-(+)-&#x394;-tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(&#x2212;)-&#x394;-tetrahydrocannabinoI composition is prepared by allowing a composition comprising (&#xb1;)-&#x394;-tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(&#x2212;)-&#x394;-tetrahydrocannabinoI composition comprising at least about 99% by weight of trans-(&#x2212;)-&#x394;-tetrahydrocannabinol based on the total amount of trans-(&#x2212;)-&#x394;-tetrahydrocannabinol and trans-(+)-&#x394;-tetrahydrocannabinol. The invention also relates to methods for treating or preventing a condition such as pain comprising administering to a patient in need thereof an effective amount of a trans-(&#x2212;)-&#x394;-tetrahydrocannabinoI having a purity of at least about 98% based on the total weight of cannabinoids.

Methods for making trans-(&#x2212;)-&#x394;-tetrahydrocannabinol and trans-(+)-&#x394;-tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(&#x2212;)-&#x394;-tetrahydrocannabinol composition is prepared by allowing a composition comprising (&#xb1;)-&#x394;)-tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(&#x2212;)-&#x394;-tetrahydrocannabinol composition comprising at least about 99% by weight of trans-(&#x2212;)-&#x394;-tetrahydrocannabinol based on the total amount of trans-(&#x2212;)-&#x394;-tetrahydrocannabinol and trans-(+)-&#x394;-tetrahydrocannabinol. The invention also relates to methods for treating or preventing a condition such as pain comprising administering to a patient in need thereof an effective amount of a trans-(&#x2212;)-&#x394;-tetrahydrocannabinol having a purity of at least about 98% based on the total weight of cannabinoids.

This invention is directed to a process for the preparation of high yield alkyl or aryl iodide from its corresponding carboxylic acid using N-iodo amides.

Process for the preparation of iodides

A novel process of preparing tridentate ligands containing one or more of a diarylphosphine and/or dialkylphosphine electron donating groups are disclosed. Use of this process for preparing a combinatorial library of such tridentate ligands and of organometallic complexes containing same is also disclosed. Further disclosed are novel diarylphosphine-containing and dialkylphosphine-containing compounds that can serve as tridentate ligands (e.g., pincer ligands), combinatorial libraries of such tridentate ligands, organometallic complexes containing these ligands (e.g., pincer complexes), and combinatorial libraries of such complexes. Methods utilizing these libraries for screening for candidate organometallic catalysts are also disclosed. Novel precursor molecules useful for preparing the tridentate ligands and processes of preparing same are also disclosed.

Diarylphosphine- and dialkylphosphine-containing compounds, processes of preparing same and uses thereof as tridentate ligands

The invention provides a novel polymorphic form I of crystalline bimatoprost, method for preparation thereof and new crystalline intermediates in the preparation. This form I of crystalline bimatoprost is used in purification of crude bimatoprost and in storage of bimatoprost as active pharmaceutical intermediate. Use of the physical form of bimatoprost in the manufacture of a medicament is also disclosed.

Bimatoprost crystalline form I

Provided are a method of making irbesartan via a Suzuki coupling reaction and a novel intermediate, 2-butyl-3-(4'-bromobenzyl)-1,3-diazaspiro[4.4]non-1-ene-4-one, for such process. The novel process includes the step of reacting such intermediate with a protected imidazolephenylboronic acid.

Synthesis of irbesartan

This invention relates to novel amorphous losartan potassium, novel losartan potassium in a crystalline form that is a hydrate, novel crystalline losartan potassium Form IV and solvates thereof, novel crystalline losartan potassium Form V and solvates thereof, to processes for their preparation, to compositions containing them and to their use in medicine. This invention further relates to a novel process for preparing crystalline losartan potassium Form I and Form II.

Amorphous and crystalline forms of losartan potassium and process for their preparation

Provided is a novel method of making 2-butyl-3-[[2'(1-trityl-1H-tetrazol-5-yl)biphen-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-ene-4-one, which can be converted to irbesartan. Also provided are methods of making irbesartan.

Synthesis of 2-butyl-3-(1-trityl-1H-tetrazol-5-YL)biphenyl-4-YL)-1,3-diazaspiro[4,4]- non-ene-4-one

Intermediates for the synthesis of irbesartan

Growing community of inventors

Haifa, Israel

Gennady Nisnevich